Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

S 15261

Known as: S-15261, S15261 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Aim:  S 15261 is a novel oral antihyperglycaemic drug with both insulin secretagogue and insulin‐sensitizing effects. The study… Expand
2005
2005
S-15261 is a new oral anti-hyperglycemic agent that increases insulin sensitivity in various insulin-resistant animal models. The… Expand
2004
2004
SummaryA new oral agent, S15261 (the L-isomer of 3- [2- [2- [4- [2- [α-fluorenyl acetyl amino ethyl] benzoyloxy] ethyl amino] 1… Expand
  • figure 1
  • table 2
  • table 3
  • figure 2
  • table 4
2000
2000
S15261, a compound developed for the oral treatment of type II diabetes, is cleaved by esterases to the fragments Y415 and S15511… Expand
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • figure 4
2000
2000
  • J. Sethi
  • IDrugs : the investigational drugs journal
  • 2000
  • Corpus ID: 32155262
This meeting focused on the recent developments in the fields of adipogensis and insulin resistance. In particular, the molecular… Expand
1998
1998
The new compound S 15261 (CAS 159978-02-6) is the I-isomer of 3-[2-[2-[4-[2-(alpha-Fluorenylacetylamino)ethyl]benzoyloxy]ethylam… Expand
1997
1997
S15261 is a novel compound that has been proposed for the treatment of insulin resistance syndrome. We have studied the effects… Expand
1997
1997
A histological study has been conducted on pancreata from insulin resistant sand rats treated with S15261. As previously shown… Expand
1995
1995
Amylin has been postulated to antagonise or inhibit the action of insulin in peripheral rat tissues and thus contribute to, or be… Expand